Top Banner
Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM
15

Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Dec 30, 2015

Download

Documents

Audra Stewart
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Summit on Drug Discovery

Tuberous Sclerosis Alliance

July 7, 2011

Biomarkers in TSC and LAM

Page 2: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Definition of a biomarker

• A characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic response to a therapeutic intervention.”

Page 3: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Types of biomarkers• Diagnostic/Screening• Risk

– Prognostic-risk of disease development or progression (e.g.-HER-2 overexpression in breast CA)

– Predictive-likelihood of response to therapy (e.g.-HER-2 overexpression in breast CA)

• Pharmacodynamic-markers of drug effect– Proximal-e.g.-phosphorylation of target kinase– Distal-e.g.-FDG-PET

• Biological progression-markers of tumor progression– Tumor markers-PSA doubling time after treatment, CTC– Anatomical imaging markers-e.g-CT scanning

• Surrogate clinical endpoints– Response, disease free survival

Page 4: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

The ideal biomarker

• Repeatable• Reproducible• Minimally invasive• Little or no risk• Inform audit trail• Reflect biology of tumor

Page 5: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Clinical ‘manifestations’ in need of diagnostic, predictive, prognostic biomarkers in TSC and LAM

• CNS– Seizures– SEGAs– Hydrocephalus– Cognition– Autism

• Renal– Renal failure– AML growth– AML bleeding– Renal cancer

• Lung (LAM)– Respiratory

insufficiency– Pneumothorax– Exercise tolerance

– Heart– Rhabdomyomas

Page 6: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Discussion of selected diagnostic, predictive, and prognostic biomarkers in TSC and LAM

• CNS– Seizures

• serial EEGs to detect & preemptively treat epileptiform activity before the first seizure

Renal– AML bleeding

• AML volume, aneurysm size and fat content on MRI imaging can be used to predict bleeding

• LAM- Diagnosis

. Circulating tumor cells

. VEGF-D-SLAM &TSCLAM

. MMP-9- Respiratory insufficiency

. Prolactin levels

. Bronchodilator response

. Menopausal status

. LAM histology score

. DLCO– Pneumothorax

• Cyst size• Collagen, MMP-1

• Heart– Rhabdomyoma

• Intrauterine ultrasound is a useful biomarker for TSC

Page 7: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Serum VEGF-D levels distinguish women with Sporadic LAM from those with other cystic lung diseases.

n=155 female subjects with definitive diagnosis by biopsy or geneticsSerum VEGF-D evaluated by ELISA (R&D Systems)

Page 8: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Elevated serum VEGF-D levels are associated with the presence of LAM in women with TSC.

Women with TSC only had a normal chest HRCT within 18 months of testing.

Young et al, Chest 2010

Page 9: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

In the MILES trial, VEGF-D declined on sirolimus

Page 10: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

In the MILES cohort, baseline serum VEGF-D correlated with

• Baseline markers of airflow obstruction, hyperinflation, diffusing capacity and quality of life

• Lung function (FVC) response to sirolimus

Page 11: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Biomarker tool kit for TSC and LAM trials

• Need biomarkers that:– Optimize patient selection– Demonstrate treatment effect earlier (target

modulation, cell/tissue effects)– Perform well as surrogate endpoints that correlate

with response and survival

Page 12: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

The Pharmacologic Audit Trail

• Effect of the drug on the target, pathway, cell, tissue

• Effect of body on the drug– PK and metabolism

• Therapeutic and toxicological effects of the drug

Sarker D. Biomarker Med 2007Sarker D. Adv Cancer Res 2007Workman P. Mol Canc Ther 2003

Page 13: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Pharmacologic audit trail

Sarker D. Biomarker Med 2007Sarker D. Adv Cancer Res 2007Workman P. Mol Canc Ther 2003

Page 14: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

John Lennon’s playlist on Omni DC Stationary for 1st US Concert at Washington Coliseum, Feb 11, 1964

• Beethoven• From Me to You• I Saw Her Standin’ There• This Boy• All My Lovin’• I Wanna Be Your Man• Please Please Me• Till There Was You• She Loves You• Twist and Shout• Long Tall Sally

Page 15: Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Group B playlist for TSC and LAM biomarker development

• Incorporate proven and exploratory biomarker analyses early and often into all phases of trials

• Consider molecular context when designing selection criteria, audit trail and surrogate endpoints for trials

• Mine data and conduct high throughput biomarker screens of serum/tissue from completed RCTs

• Establish functional and efficient central repository for TSC data and tissue